Stocks · News reference

LifeMD Sees Q3 Sales $48.000M-$51.000M vs $58.547M Est

Aug 5, 2026, 8:49 PMBenzinga Newsdesk

LifeMD (NASDAQ:LFMD) sees Q3 sales of $48.000 million-$51.000 million vs $58.547 million analyst estimate.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 5, 2026, 8:49 PM
Checked: Aug 5, 2026, 8:49 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 1, 2026, 6:04 PMBenzinga Newsdesk
FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
CI CVS ELV HIMS LFMD
BenzingaAug 7, 2026, 1:07 PMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $9
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $9.
LFMD
BenzingaAug 6, 2026, 1:58 PMBenzinga Newsdesk
B. Riley Securities Maintains Buy on LifeMD, Lowers Price Target to $8
B. Riley Securities analyst William Woods maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $8.
LFMD
BenzingaAug 6, 2026, 1:24 PMBenzinga Newsdesk
LifeMD shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 sales guidance. Also, the company issued Q3 sales guidance below estimates.
LFMD